Need for concurrent other cytoreductive chemotherapy Patients may not receive any cancer-directed concurrent therapy, such as concurrent chemotherapy, radiotherapy, or hormonal therapy while on study Prior or concurrent antineoplastic agents (chemotherapy) Patients must be having concurrent chemotherapy Planned concurrent chemotherapy or anti-tumor agent during PCI Prior chemotherapy if this precludes administration of concurrent chemotherapy for protocol treatment; note that induction chemotherapy is allowed as long as concurrent chemotherapy is possible Concurrent chronic systemic immunotherapy, chemotherapy or hormone therapy Receiving concurrent immunotherapy or chemotherapy No concurrent XRT or chemotherapy is allowed Planned treatment with radiation therapy alone without concurrent chemotherapy or chemotherapy alone Patients that receive concurrent chemotherapy with the exception of concurrent vincristine Chemotherapy concurrent with SBRT is not allowed Patients must not be planning to receive any concurrent cytotoxic chemotherapy, surgery or radiation therapy during protocol treatment Patients receiving concurrent chemotherapy, radiation therapy, or immunotherapy for AML No concurrent chemotherapy Concurrent therapy\r\n* The concurrent use of bevacizumab is allowed if previously initiated for tumor progression or symptomatic management; prior temozolomide or other cytotoxic chemotherapy is allowed Patients with concurrent cytotoxic chemotherapy or radiation therapy Patients cannot tolerate concurrent chemotherapy Concurrent chemotherapy (except intrathecal chemotherapy) Concurrent chemotherapy is allowed, but not required Previous or concurrent systemic or targeted chemotherapy is allowed Radiation treatment alone without concurrent chemotherapy or chemotherapy use alone Concurrent chemotherapy (no chemotherapy starting days before start of radiation Concurrent chemotherapy Concurrent chemotherapy or biologic therapy Patients may receive no other concurrent chemotherapy or radiation therapy during this trial Concurrent chemotherapy (no chemotherapy starting days before start of radiation) Concurrent chemotherapy Patients may not be receiving concurrent chemotherapy for treatment of metastatic disease Patient receiving any concurrent chemotherapy Patient receiving any concurrent chemotherapy Patient receiving any concurrent chemotherapy Concurrent chemotherapy or biologic therapy Concurrent chemotherapy is not allowed Receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent; NOTE: Concurrent intrathecal chemotherapy for CNS prophylaxis allowed per institutional standards Other concurrent chemotherapy Concurrent immunotherapy, chemotherapy, or radiation therapy for duration of subject participation on study Subjects undergoing concurrent chemotherapy, radiation therapy, immunotherapy are excluded Concurrent chemotherapy (no chemotherapy starting days before start of radiation) Concurrent chemotherapy Patients undergoing concurrent cytotoxic chemotherapy and radiation therapy (concurrent Herceptin and/or tamoxifen/aromatase inhibitor allowed) Planned concurrent chemotherapy or antitumoral agent during PCI Concurrent radiation therapy or chemotherapy Is not receiving concurrent cytotoxic chemotherapy and/or radiation therapy at time of enrollment AND, if randomized, is not anticipated that the participant will need to receive concurrent cytotoxic chemotherapy and/or radiation therapy at any time during the aim intervention Recommended to undergo IMRT or PBT of the pelvis with concurrent chemotherapy Concurrent chemotherapy (biologic agents are allowed) Concurrent enrollment in another clinical study where they are receiving non-standard salvage chemotherapy, (i.e., concurrent enrollment is allowable if the patient is receiving standard salvage chemotherapy and research imaging is allowed) No concurrent chemotherapy